Dongin (Donoven) Kim, Ph.D.

Prof,Asst

Pharmaceutical Sciences

Phone (405) 271-6593 x 47473

Office COP200

Email dongin-kim@ou.edu

Publications & Presentations

1 2 3 4 > >>
    1. Daly M B, Kim D, Krovi A, Li L, Norton C A, Gatto G J, Khalil G, Brake M, Wier R, Mitchell J, Johnson R, Dinh C, Edwards T E, Haaland R, Lipscomb J, Cottrell M, Heneine W, García-Lerma J G, Johnson L M, Dobard C W. A subcutaneous implant that releases islatravir provides long-lasting protection against vaginal SHIV infection in macaques. Journal of controlled release : official journal of the Controlled Release Society. 2026; 390 : 114575

    2. Jiang Z, Bi F, Ge Z, Mansolf M, Hartwich T, Kolesnyk V, Yang K, Park W, Kim D, Grechukhina O, Hui P, Kim S, Yang-Hartwich Y. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer . Cancers. 2025; 17

    3. Firouzi M, Kang C, Ren X, Jung W, Abushukair H, Hartwich T, Ramesh R, Yoon J, Yang-Hartwich Y, Oh T, Kim D. Antibody Generation Using Cancer-Derived Small Extracellular Vesicles (sEVs): A Platform for Targeted Cancer Therapy and Potential Personalized Applications. Small. 2025

    4. Chen Y, Bounds S E, Kundu N, Karmoker J R, Liu Y, Kim D, Cai J. Role of MiR-204 in controlling metabolic functions of the subretinal microglia. Theranostics. 2025; 15 : 8952-8963

    5. Horwitz D W, Kim D, Kang C, Brion K, Bickerton S, Gava A L. CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-b producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders . Frontiers in Immunology. 2025; 15 : 8952-8963

1 2 3 4 > >>



Grants

1 2 3 >>
    1. Drug-Targeting ORP4 as a Precision Ovarian Cancer Target. DOD. Start Date: 2025. End Date: 2029.

    2. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.

    3. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.

    4. Preclinical assessment of exosomal drug delivery system using innovative tumor mouse model. Misc Non-Federal. Start Date: 2024. End Date: 2026.

    5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

1 2 3 >>



Awards and Honors


no results

Education

                                                                                            1.  Degree: Ph D. University of Utah. Date: 2009.  

                                                                                            2.  Degree: MS. University of Florida. Date: 2002.  

                                                                                            3.  Degree: BS. Ajou University. Date: 1999.  




                        		 
                                                                                  
                        
                                                                               
 
                   
 
                
     
                
                 	                                        
                    
                                            	                           
                                                
                                                                                                                                                                               
Administrative Assignments

                                  
                                                           
                        
no results